Biocon in licensing deals in N America, Europe

MUMBAI: Biocon has entered into a licensing agreement with a global biopharmaceutical company to develop and market a bio-similar version of granulocyte-colony stimulating factor in North America and the European Union.

Under the agreement, Biocon will receive an upfront licensing fee, and following approval in the licensed territories, royalties from sales.

At 10:54 am, the Biocon share was up 2.91% at Rs 474 with volume traded at 1,56,220 against two-week average of 1,31,505 shares. The share was up also ahead of the company’s first quarter earnings expected later today.

Biocon has also signed an exclusive agreement with Invitrogen Corporation to market pharmaceutical-grade insulin in the global cell culture market.

The company has filed an investigational medical product dossier for IN 105 to conduct Phase I clinical trial in Sweden. The trial will be conducted at Karolinska University Hospital in Stockholm.